webinar recording available - register to watch

New data: How ctDNA is evolving oncology patient management and drug development

This webinar will explore the rapidly evolving role of circulating tumor DNA (ctDNA) in identifying patients at high risk of relapse and in monitoring treatment response, with significant applications for biopharma drug development and clinical practice.

Our expert speakers will discuss the latest 2022 data from ASCO, AACR, and ASCO GI supporting the use of ctDNA across applications and solid tumor types. This will be followed by a panel discussion on the future directions and implications that can be derived from ctDNA data.

Data presented will span treatment settings and tumor types, including:

Colorectal cancer:

  • Recent interim analyses from CIRCULATE-Japan, a 1,000+ patient prospective study demonstrating that ctDNA can be predictive of adjuvant chemotherapy benefit
  • Latest data from other ongoing ctDNA-guided studies, showing that ctDNA-guided therapy substantially reduced the proportion of patients receiving adjuvant therapy without compromising RFS at 2 years

Breast cancer:

  • Latest I-SPY-2 data demonstrating association of pathological complete response (pCR), residual cancer burden (RCB), and ctDNA
  • The full data set from EBLIS, the largest breast cancer cohort with the longest monitoring of patients with ctDNA (up to 12 years), demonstrating that serial postoperative ctDNA analysis has a strong prognostic value

Lung cancer:

  • New data at ASCO demonstrating MRD detection by ctDNA is predictive of disease recurrence in stage I-III NSCLC patients undergoing definitive radiotherapy, and may help identify patients who would benefit from systemic therapy intensification.
watch now
watch the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Angel Rodriguez

Angel Rodriguez

Oncology Medical Director, Natera

Angel Augusto Rodriguez, MD, is a board-certified medical oncologist who specializes in breast medical oncology and conducted clinical research with circulating tumor DNA. Before joining Natera, Dr. Rodriguez practiced at Austin Cancer Centers and Houston Methodist Cancer Center where he was Director of the Clinical Trials Office and the Triple Negative Breast Cancer Clinic. While at Houston Methodist he was the principal investigator of clinical trials and conducted clinical research with circulating tumor DNA.

Adham Jurdi

Adham Jurdi

Oncology Medical Director, Natera

Adham Jurdi, MD, is a Board-certified Medical Oncologist who specializes in gastrointestinal malignancies. Prior to joining Natera, Dr Jurdi practiced at Austin Cancer Center, SUNY Upstate Medical University and the Syracuse VAMC. Throughout his clinical career, he was involved in GI oncology and precision medicine research

Michael Krainock

Michael Krainock

Oncology Associate Medical Director, Natera

Michael Krainock, MD, PhD, is a Medical Director in Thoracic Oncology at Natera. Mike is a physician-scientist by training with experience in biotechnology and life sciences innovation. After completing his medical degree at the University of Nevada, Michael went on to earn a PhD at the University of Southern California, studying the epigenetic regulation of epithelial-to-mesenchymal transformation. Michael completed residency training in general surgery at Loma Linda University Medical Center and fellowship training in cardiothoracic surgery at the University of Pittsburgh Medical Center. Michael has also received an MBA from the Gies College of Business - University of Illinois.

John Simmons

John Simmons

Global VP Biopharma, Natera

John Simmons, PhD currently leads oncology biopharma partnerships at Natera. Before joining Natera, John completed his postdoctoral fellowship at the National Cancer Institute (NCI) and served as Vice President of Translational Medicine at Personal Genome Diagnostics (PGDx). He received his PhD in Tumor Biology from Georgetown University.

Arsalan Arif
moderator

Arsalan Arif

Founder & publisher, endpoints news

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.